Muscarinic drugs breathe new life into schizophrenia pipeline

IF 122.7 1区医学 Q1 BIOTECHNOLOGY & APPLIED MICROBIOLOGY

Nature Reviews. Drug Discovery Pub Date : 2024-07-30 DOI:10.1038/d41573-024-00129-w

Katie Kingwell

引用次数: 0

Abstract

Karuna and Bristol Myers Squibb’s muscarinic agonist KarXT looks set to offer the first new drug mechanism for patients with schizophrenia in over 70 years. Karuna and Bristol Myers Squibb’s muscarinic agonist KarXT looks set to offer the first new drug mechanism for patients with schizophrenia in over 70 years.

Abstract Image

查看原文本刊更多论文

毒蕈碱类药物为精神分裂症的治疗注入了新的活力。

卡鲁纳和布里斯托尔-迈尔斯-施贵宝公司的毒蕈碱激动剂KarXT有望为精神分裂症患者提供70多年来首个新的药物机制。卡鲁纳和布里斯托尔-迈尔斯-施贵宝公司的毒蕈碱激动剂 KarXT 看来将为精神分裂症患者提供 70 多年来的首个新药物机制。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Nature Reviews. Drug Discovery 医学-生物工程与应用微生物

CiteScore

137.40

自引率

0.30%

发文量

227

期刊介绍： Nature Reviews Drug Discovery is a monthly journal aimed at everyone working in the drug discovery and development arena. Each issue includes: Highest-quality reviews and perspectives covering a broad scope. News stories investigating the hottest topics in drug discovery. Timely summaries of key primary research papers. Concise updates on the latest advances in areas such as new drug approvals, patent law, and emerging industry trends and strategies.